Teva Pharmaceutical Industries (TEVA) Given “Hold” Rating at Wells Fargo & Co

Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “hold” rating reaffirmed by equities researchers at Wells Fargo & Co in a research note issued to investors on Thursday. They presently have a $20.00 target price on the stock, down from their previous target price of $24.00. Wells Fargo & Co‘s price objective indicates a potential upside of 15.61% from the company’s current price. The analysts noted that the move was a valuation call.

A number of other equities analysts have also issued reports on TEVA. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Monday, December 3rd. ValuEngine cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Monday. Royal Bank of Canada set a $22.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Friday, November 2nd. Finally, Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, November 1st. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $22.39.

Shares of NYSE TEVA traded down $0.33 during mid-day trading on Thursday, reaching $17.30. The company had a trading volume of 16,212,911 shares, compared to its average volume of 10,017,625. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75. The stock has a market cap of $19.44 billion, a PE ratio of 4.40, a PEG ratio of 5.83 and a beta of 1.46. Teva Pharmaceutical Industries has a 52 week low of $14.59 and a 52 week high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, February 13th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The company had revenue of $4.56 billion for the quarter, compared to analysts’ expectations of $4.52 billion. During the same period in the prior year, the business earned $0.93 EPS. The firm’s quarterly revenue was down 15.5% on a year-over-year basis. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.82 earnings per share for the current year.

In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 1,643 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $15.70, for a total transaction of $25,795.10. Following the sale, the vice president now owns 13,469 shares of the company’s stock, valued at approximately $211,463.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Notaristefani Carlo De sold 5,041 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $17.88, for a total value of $90,133.08. Following the sale, the vice president now directly owns 17,162 shares in the company, valued at approximately $306,856.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,617 shares of company stock valued at $136,230. Insiders own 0.43% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Brahman Capital Corp. grew its stake in Teva Pharmaceutical Industries by 67.3% in the fourth quarter. Brahman Capital Corp. now owns 12,248,106 shares of the company’s stock valued at $188,866,000 after purchasing an additional 4,925,245 shares in the last quarter. FMR LLC boosted its stake in shares of Teva Pharmaceutical Industries by 19.1% during the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock worth $527,341,000 after acquiring an additional 3,921,785 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its position in shares of Teva Pharmaceutical Industries by 6,156.1% during the 4th quarter. Menora Mivtachim Holdings LTD. now owns 3,658,479 shares of the company’s stock worth $56,414,000 after purchasing an additional 3,600,000 shares during the last quarter. Beck Mack & Oliver LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $64,484,000. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 99.9% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,715,499 shares of the company’s stock worth $88,133,000 after purchasing an additional 2,855,802 shares during the last quarter. Institutional investors and hedge funds own 62.11% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Put Option

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply